CA-HEPTAGON
22.2.2016 08:02:35 CET | Business Wire | Press release
Heptagon (www.hptg.com ), an industry leader in 3D imaging, sensing and illumination solutions for the Internet of Things (IoT) and Smart Devices, today announced it has shipped over 2 billion units to customers. The company, which is headquartered in Singapore, recently opened a new factory with expanded capacity to ship 1 billion units per year. Heptagon serves some of the largest makers of mobile and IoT products in the world. Its success is attributed to relentless dedication to innovation, consistently delivering top-quality, high-performance products to market quickly, and leading edge wafer level manufacturing capabilities that meet the needs of the fast-paced and rapidly-evolving IoT and smart device industries.
"We are delighted to announce this latest milestone in our rapid growth and see this as ongoing acceptance by the market of our innovative, world-class products," says Christian Tang-Jespersen, CEO and President of Heptagon. "We look forward to continuing our strong growth and reaching our next billion units shipped milestone.”
"We are well positioned to pursue new market opportunities with the expansion of our fab in Woodlands, Singapore and the opening of our new factory in Ang Mo Kio, Singapore," says S.C. Leong, Heptagon’s Chief Operating Officer. “We remain committed to uncompromising quality and our proven ability to move quickly from white board to shipping 100s of millions of units."
In addition to opening the new factory in Singapore, Heptagon has expanded its sales, marketing and engineering presence in Silicon Valley as a result of strong customer interest in the company’s product and miniaturization, integration, optical and electrical design expertise. Heptagon’s newly created Silicon Valley Labs and Executive Briefing Center showcase the latest interface and sensing technologies while providing convenient access for the innovators and decision makers in Silicon Valley.
With in-depth and unique knowledge and expertise in all major 3D imaging and sensing technologies including stereo vision, structured light and Time-of-Flight (ToF), Heptagon is ready to address a fast-growing market segment of 3D. The company’s products continue to push the boundaries of what is possible in 3D today. As a pioneer of ToF imaging, it recently introduced the industry’s first multipoint 3D ranging sensor for mobile application. Further, its proprietary technologies like adaptive stereo enables indoor and outdoor imaging in a single solution and create a unique platform for 3D capturing where the adaptive illumination technology powers interference free multi-user applications as needed in collaborative augmented reality, automotive cockpits and digital signage.
The need to integrate heterogeneous technologies in miniaturized packages is rapidly becoming the enabler of next generation products in mobile, wearables and IoT. Over 20 years of innovation in technology, manufacturing and operations, as well as a rigorous supply chain management form the foundation for Heptagon’s differentiation and uniquely positions the company to innovate and rapidly bring world-class products to market.
About Heptagon
Heptagon (www.hptg.com ) provides complete 3D/imaging, illumination and optical sensing solutions for smart devices and the internet of things. With over 2 billion units shipped and 20 years of industry firsts in miniaturizing and integrating complex hardware and software systems, Heptagon has industry leading technology and services to enhance our customer’s competitiveness. Backed by world-class investors, Heptagon is a global company with research and development, sales and customer services teams located in Singapore, Zurich Switzerland, in Silicon Valley USA, and Shenzhen China.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160221005200/en/
Contact:
Heptagon
Scott Filler +1 408-329-8920
pr@hptg.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom